Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 181,325 | 158,320 | 411,535 | 501,142 | 594,116 |
| Marketable Securities | 469,289 | 627,265 | 499,950 | 246,835 | N/A |
| Receivables | 33,616 | 30,590 | 38,593 | 160,576 | 213,239 |
| Other current assets | 67,140 | 55,810 | 75,413 | 21,247 | 5,970 |
| TOTAL | $751,370 | $871,985 | $1,025,491 | $929,800 | $813,325 |
| Non-Current Assets | |||||
| PPE Net | 340,429 | 287,696 | 217,255 | 111,616 | 17,923 |
| Investments And Advances | 82,297 | 65,938 | 72,522 | 50,313 | 19,247 |
| Intangibles | 89,919 | 168,231 | 179,308 | 196,198 | 146,653 |
| Other Non-Current Assets | 96,538 | 94,244 | 46,331 | 30,642 | 8,388 |
| TOTAL | $609,183 | $616,109 | $515,416 | $388,769 | $192,211 |
| Total Assets | $1,360,553 | $1,488,094 | $1,540,907 | $1,318,569 | $1,005,536 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 63,091 | 100,055 | 96,708 | 54,951 | 33,606 |
| Accrued Expenses | N/A | N/A | N/A | 22,506 | 27,143 |
| TOTAL | $76,612 | $119,013 | $118,320 | $120,676 | $103,490 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 13,521 | 18,958 | 21,612 | 7,536 | 6,589 |
| Other Non-Current Liabilities | 62,212 | 82,041 | 95,815 | 74,032 | 19,483 |
| TOTAL | $227,857 | $216,763 | $189,310 | $172,160 | $71,538 |
| Total Liabilities | $304,469 | $335,776 | $307,630 | $292,836 | $175,028 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 297,988 | 292,782 | 287,686 | 283,924 | N/A |
| Common Shares | 777,171 | 753,199 | 734,365 | 722,430 | 710,387 |
| Retained earnings | 116,930 | 279,787 | 426,185 | 267,666 | 114,202 |
| Other shareholders' equity | -4,378 | -1,720 | -1,391 | 280 | 0 |
| TOTAL | $1,056,084 | $1,152,318 | $1,233,277 | $1,025,733 | $830,508 |
| Total Liabilities And Equity | $1,360,553 | $1,488,094 | $1,540,907 | $1,318,569 | $1,005,536 |